Deal with Macrogenics (NASDAQ:MGNX)
Synaffix signs out-licensing deal with Macrogenics worth up to $586m

February 2022
Deal with Genmab (NASDAQ:GMAB)
Synaffix signs exclusive out-licensing deal with Genmab worth up to $415m

January 2022
Deal with Mersana (NASDAQ:MRSN) Expanded
Synaffix expands the 2019 deal with Mersana to over $1 billion.

November 2021
Deal with Kyowa Kirin (TYO:4151)
Kyowa Kirin Taps Synaffix ADC Technology to Expand Its Pipeline

August 2021
Deal with ProfoundBio
Synaffix signs out-licensing deal with ProfoundBio worth up to $246m

July 2021
Deal with Innovent (1801:HK)
Synaffix signs out-licensing deal with Innovent, providing access to GlycoConnect™, HydraSpace™ and toxSYN™ platforms for ADC development and commercialization

June 2021
Winner "Best ADC Platform Technology" Award
Synaffix awarded “Best ADC Platform Technology” at World ADC Awards ceremony

Sept 2020
Deal with Miracogen
Synaffix signs out-licensing deal with Miracogen worth up to $125m

Apr 2019
Deal with Mersana (NASDAQ:MRSN)
Synaffix signs out-licensing deal with Mersana worth up to $295m

Jan 2019
toxSYN™ Linker-Payloads Launched
Synaffix launches toxSYN™ linker-payloads as extension of its existing platform, enabling any company with an antibody to develop proprietary, best-in-class ADCs

Dec 2017
Deal with ADC Therapeutics (NYSE:ADCT)
Synaffix signs initial out-licensing deal with ADC Therapeutics, providing access to GlycoConnect™ and HydraSpace™ for ADC development and commercialization

Oct 2016
High Potency Lab Opens
High potency lab comes online, facilitating safe handling of highly-potent ADCs and ADC payloads

Feb 2016
SAB Established
Leading industry experts appointed to Scientific Advisory Board (SAB)

Jan 2016
Series A Financing

2014
Series A financing, backed by top-tier investor syndicate including Aravis, BioGeneration Ventures, BOM Capital and M Ventures

toxSYN™ Linker-Payloads - Model DAR - Drug Antibody Ratio